Amid GLP-1 ma­nia, health tech's weight loss star­tups are try­ing to prove their ser­vices mat­ter

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

The ram­pant suc­cess of new pre­scrip­tion GLP-1 drugs has turned out to be both a tail­wind and a huge risk for health tech’s emerg­ing group of weight loss man­age­ment com­pa­nies.

Cal­i­brate, which made its name as a place where peo­ple could go to get ac­cess to the drugs in the ear­ly days of ap­provals, is in­creas­ing­ly fac­ing com­pe­ti­tion from com­pa­nies like Noom and Weight­Watch­ers — and even drug­mak­er Eli Lil­ly to be the place to go when seek­ing pre­scrip­tion weight loss care. To stay com­pet­i­tive, Cal­i­brate and com­pa­nies like it have to show ev­i­dence that their ap­proach­es go fur­ther than pro­vid­ing ac­cess to weight loss med­ica­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER